Research
Hormonal
DPP-4 inhibitors (Sitagliptin, Saxagliptin, Alogliptin, Linagliptin) are generally neutral for cardiovascular outcomes, with specific agents (Saxagliptin, Alogliptin) associated with an increased risk of heart failure hospitalization.
If you have Type 2 Diabetes and Heart Failure, avoid Saxagliptin and Alogliptin. DPP-4 inhibitors are generally neutral for heart health; prefer SGLT2 inhibitors or GLP-1 agonists which offer proven cardiovascular benefits.
GoodQualifiesHIGH confidence
A meta-analysis of these trials reaffirmed that DPP-4 inhibitors do not improve or worsen CV outcomes in T2DM, with no significantly increased risk of HF hospitalizations. Although later analyses have not revealed a significant association between DPP-4 inhibitor use and HF hospitalizations, major guidelines currently do not recommend saxagliptin and alogliptin for the management of T2DM in patients with HF.
Why this rating
Based on multiple RCTs (TECOS, SAVOR-TIMI 53, EXAMINE, CARMELINA).
Source
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure
Khawaja M. Talha et al. · Methodist DeBakey Cardiovascular Journal · 2022
DOI 10.14797/mdcvj.1155
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) significantly reduce major adverse cardiovascular events (MACE-3), cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.Strong
- GLP-1 receptor agonists (Liraglutide, Semaglutide, Dulaglutide, Albiglutide, Efpeglenatide) significantly reduce MACE-3 and cardiovascular death in patients with Type 2 Diabetes and high cardiovascular risk.Strong
- SGLT2 inhibitors significantly reduce heart failure hospitalizations and cardiovascular death in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF), regardless of diabetes status.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →